Bactolife Revenue and Competitors
Employee Data
- Bactolife has 61 Employees.
- Bactolife grew their employee count by 20% last year.
Bactolife's People
Name | Title | Email/Phone |
---|
Bactolife Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | N/A | 61 | 20% | N/A | N/A |
#2 | N/A | 14 | 0% | N/A | N/A |
#3 | N/A | 25 | 4% | N/A | N/A |
#4 | N/A | 33 | 94% | N/A | N/A |
#5 | N/A | 21 | 24% | N/A | N/A |
#6 | N/A | 6 | 100% | N/A | N/A |
#7 | N/A | 22 | 5% | N/A | N/A |
#8 | N/A | 26 | 37% | N/A | N/A |
#9 | N/A | 12 | 50% | N/A | N/A |
What Is Bactolife?
We are on a mission to enhance global gut health and support the fight against antimicrobial resistance. \n \nAs a Danish biotech firm, we are pioneering the future of gut health with our unique food ingredient, Binding Proteins. \n \nBinding Proteins are natural and versatile enough for any food, beverage, or supplement, selectively bind and block harmful microbial activity without disturbing the beneficial microbiome. \n \nOur food ingredients are specially formulated for diverse needs, benefiting everyone from mothers and children to the elderly, immune-compromised individuals, travelers, and even animals. Backed by investors such as Novo Holdings, the Bill & Melinda Gates Foundation, and Innovation Fund Denmark, we are committed to making Binding Proteins widely available. Our vision is a future where these proteins are a common part of diets, supporting gut health globally. \n \nOur deep understanding of Binding Proteins, combined with competitive pricing, enables us to make these innovations accessible. \n \nJoin us as we change the future of gut health one Binding Protein at a time.
keywords:N/AN/A
Total Funding
61
Number of Employees
N/A
Revenue (est)
20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $8M | 61 | 3% | N/A |
#2 | $7.5M | 61 | 7% | N/A |
#3 | N/A | 62 | 24% | N/A |
#4 | $10.5M | 62 | 44% | N/A |
#5 | N/A | 63 | 3% | N/A |